Treatment of multiple sclerosis.
作者信息
Pandit Lekha, Murthy J M K
机构信息
Department of Neurology, KS Hegde Medical Academy, Nitte University, Mangalore, Karnataka, India.
出版信息
Ann Indian Acad Neurol. 2011 Jul;14(Suppl 1):S65-9. doi: 10.4103/0972-2327.83094.
Abstract
摘要
相似文献
1
Treatment of multiple sclerosis.多发性硬化症的治疗。
Ann Indian Acad Neurol. 2011 Jul;14(Suppl 1):S65-9. doi: 10.4103/0972-2327.83094.
2
Treatment of children and adolescents with multiple sclerosis.儿童和青少年多发性硬化症的治疗。
Expert Rev Neurother. 2005 May;5(3):391-401. doi: 10.1586/14737175.5.3.391.
3
Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm.早期和晚期多发性硬化症的疾病修正治疗：一种新的治疗模式。
Curr Opin Neurol. 2018 Jun;31(3):233-243. doi: 10.1097/WCO.0000000000000561.
4
Good results for early treatment of clinically isolated syndrome prior to multiple sclerosis with interferon beta-1b and glatiramer group.早期采用干扰素β-1b 和格拉替雷治疗临床孤立综合征可获得良好效果，以预防多发性硬化症。
Expert Opin Pharmacother. 2010 May;11(7):1225-30. doi: 10.1517/14656561003677390.
5
[Differential diagnosis of multiple sclerosis with pediatric onset: the experience of the Moscow Division for treatment of children and adolescents with multiple sclerosis].小儿多发性硬化的鉴别诊断：莫斯科儿童及青少年多发性硬化治疗中心的经验
Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(10 Pt 2):61-8.
6
Assessing the values of circulating immune complexes in multiple sclerosis patients following immunomodulator or corticosteroid treatment.评估免疫调节剂或皮质类固醇治疗后多发性硬化症患者循环免疫复合物的价值。
Exp Ther Med. 2021 May;21(5):542. doi: 10.3892/etm.2021.9974. Epub 2021 Mar 23.
7
A consensus initiative for the assessment of patients newly diagnosed with multiple sclerosis in Spain: the eXamina Project.西班牙一项针对新诊断多发性硬化症患者评估的共识倡议：eXamina项目。
Neurodegener Dis Manag. 2016 Oct;6(5):363-74. doi: 10.2217/nmt-2016-0024. Epub 2016 Sep 7.
8
Pathogenesis of pediatric multiple sclerosis.儿童多发性硬化症的发病机制。
J Child Neurol. 2012 Nov;27(11):1394-407. doi: 10.1177/0883073812456084. Epub 2012 Sep 5.
9
[Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis].[使用克拉屈滨（片剂）治疗缓解型多发性硬化症成年患者的药物经济学方面]
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(8):30-36. doi: 10.17116/jnevro202112108130.
10
[Prevalence and impact of comorbidities in patients with multiple sclerosis].[多发性硬化症患者合并症的患病率及影响]
Rev Neurol. 2020 Aug 16;71(4):151-158. doi: 10.33588/rn.7104.2020095.
引用本文的文献
1
Effectiveness of disease-modifying agents in ameliorating multiple sclerosis - A cross-sectional observational study.疾病修饰药物改善多发性硬化症的有效性——一项横断面观察性研究。
Indian J Pharmacol. 2025 Mar 1;57(2):90-96. doi: 10.4103/ijp.ijp_493_23. Epub 2025 Jun 13.
2
Study to Compare the Efficacy and Cost-Effectiveness of Various Disease Modifying Drugs in the Management of Multiple Sclerosis in India- An Observational Study.比较多种疾病修正药物治疗印度多发性硬化症的疗效和成本效益的研究——一项观察性研究。
Ann Indian Acad Neurol. 2023 Nov-Dec;26(6):895-901. doi: 10.4103/aian.aian_467_23. Epub 2023 Sep 27.
3
Autologous Hematopoietic Stem Cell Transplantation (AHSCT): An Evolving Treatment Avenue in Multiple Sclerosis.自体造血干细胞移植（AHSCT）：多发性硬化症中不断发展的治疗途径。
Biologics. 2021 Mar 2;15:53-59. doi: 10.2147/BTT.S267277. eCollection 2021.
4
Hydrogels Derivatized With Cationic Moieties or Functional Peptides as Efficient Supports for Neural Stem Cells.用阳离子部分或功能性肽衍生化的水凝胶作为神经干细胞的有效载体。
Front Neurosci. 2020 May 20;14:475. doi: 10.3389/fnins.2020.00475. eCollection 2020.
5
Optic neuritis, its differential diagnosis and management.视神经炎、其鉴别诊断及管理
Open Ophthalmol J. 2012;6:65-72. doi: 10.2174/1874364101206010065. Epub 2012 Jul 24.
本文引用的文献
1
Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?米托蒽醌相关的治疗相关性急性白血病：风险是什么，我们能否将其降至最低？
Mult Scler. 2009 Apr;15(4):505-8. doi: 10.1177/1352458508100967. Epub 2009 Feb 27.
2
Disease-modifying therapy in multiple sclerosis: update and clinical implications.多发性硬化症的疾病修正治疗：最新进展及临床意义
Neurology. 2008 Dec 9;71(24 Suppl 3):S8-13. doi: 10.1212/WNL.0b013e31818f3d8b.
3
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.抗那他珠单抗抗体的发生率及意义：来自AFFIRM和SENTINEL研究的结果
Neurology. 2007 Oct 2;69(14):1391-403. doi: 10.1212/01.wnl.0000277457.17420.b5. Epub 2007 Aug 29.
4
Longitudinal follow-up of "benign" multiple sclerosis at 20 years.“良性”多发性硬化症20年的纵向随访
Neurology. 2007 Aug 28;69(9):938; author reply 938-9. doi: 10.1212/01.wnl.0000281903.32474.15.
5
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.复发缓解型多发性硬化症患者的长期皮下注射干扰素β-1a治疗
Neurology. 2006 Sep 26;67(6):944-53. doi: 10.1212/01.wnl.0000237994.95410.ce.
6
Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society.多发性硬化的对症治疗。德国多发性硬化协会多发性硬化治疗共识小组（MSTCG）
Eur Neurol. 2006;56(2):78-105. doi: 10.1159/000095699. Epub 2006 Sep 8.
7
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.使用β-1b干扰素治疗可延缓临床孤立综合征患者转变为临床确诊的多发性硬化症及符合麦克唐纳标准的多发性硬化症。
Neurology. 2006 Oct 10;67(7):1242-9. doi: 10.1212/01.wnl.0000237641.33768.8d. Epub 2006 Aug 16.
8
Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.进行性多灶性白质脑病并发那他珠单抗和干扰素β-1a治疗多发性硬化症。
N Engl J Med. 2005 Jul 28;353(4):369-74. doi: 10.1056/NEJMoa051782. Epub 2005 Jun 9.
9
Rationale for the use of mitoxantrone in multiple sclerosis.米托蒽醌用于多发性硬化症的理论依据。
J Neurol Sci. 2004 Aug 15;223(1):35-9. doi: 10.1016/j.jns.2004.04.017.
10
Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED].多发性硬化症的疾病修饰疗法：美国神经病学学会治疗与技术评估小组委员会及MS临床实践指南理事会报告[已退休]
Neurology. 2002 Jan 22;58(2):169-78. doi: 10.1212/wnl.58.2.169.
Zotero 插件